Healthcare Sector Performance: The S&P healthcare index (XLV) experienced a YTD increase of 12.2% by mid-December 2025, ranking as the sixth-highest performing sector among the 11 S&P 500 indexes.
Top Life Sciences Stocks: Adaptive Biotechnologies Corporation (ADPT) led the Life Sciences Tools and Services stocks with a YTD performance of +183.57%, followed by Tempus AI (TEM) and Medpace Holdings (MEDP) with +90.94% and +71.07%, respectively.
Additional Top Performers: Other notable performers in the top five include Sotera Health (SHC) at +25.51% and Mettler-Toledo International (MTD) at +14.61%, all maintaining a "Hold" rating.
Healthcare ETFs: Various healthcare ETFs such as XLV, VHT, and IHI are mentioned, alongside predictions for sector outperformers and laggards in 2026.
Wall Street analysts forecast ADPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADPT is 20.25 USD with a low forecast of 20.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast ADPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADPT is 20.25 USD with a low forecast of 20.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 17.570
Low
20.00
Averages
20.25
High
21.00
Current: 17.570
Low
20.00
Averages
20.25
High
21.00
TD Cowen
Buy
maintain
$19 -> $20
2026-01-07
Reason
TD Cowen
Price Target
$19 -> $20
AI Analysis
2026-01-07
maintain
Buy
Reason
TD Cowen raised the firm's price target on Adaptive Biotechnologies to $20 from $19 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics group as part of a Q4 preview. It expects solid results and 2026 outlooks for the sector, saying strong fundamentals remain.
Morgan Stanley
Tejas Savant
Equal Weight
maintain
$11 -> $16
2025-11-11
Reason
Morgan Stanley
Tejas Savant
Price Target
$11 -> $16
2025-11-11
maintain
Equal Weight
Reason
Morgan Stanley analyst Tejas Savant raised the firm's price target on Adaptive Biotechnologies to $16 from $11 and keeps an Equal Weight rating on the shares following the company's recent Q3 report.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ADPT
Unlock Now
JPMorgan
Rachel Vatnsdal
maintain
$17 -> $20
2025-11-06
Reason
JPMorgan
Rachel Vatnsdal
Price Target
$17 -> $20
2025-11-06
maintain
Reason
JPMorgan analyst Rachel Vatnsdal raised the firm's price target on Adaptive Biotechnologies to $20 from $17 and keeps an Overweight rating on the shares following the Q3 report.
Piper Sandler
Overweight
maintain
$15 -> $20
2025-10-15
Reason
Piper Sandler
Price Target
$15 -> $20
2025-10-15
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Adaptive Biotechnologies to $20 from $15 and keeps an Overweight rating on the shares. The firm notes it surveyed 59 doctors but focused on the 28 who see blood cancers. From its survey, Adaptive continues to stand out as an underappreciated stock in the MRD space, holding the second-highest revenues and volumes specifically linked to minimal residual disease detection, and serving the most covered lives. Piper believes the company has significant growth potential, projecting approximately 30% increases in both volume over the next few years, driven by expanded EMR adoption, recent strategic partnerships, blood-based testing options, and ongoing clinical trials.
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
